Atara Biotherapeutics Inc (ATRA)

Over the past six months, Atara completed the transfer of tab-cel operational activities to Pierre Fabre Laboratories and resubmitted its BLA for tabelecleucel to the FDA. The FDA accepted the BLA and granted it Priority Review with a target action date of January 10, 2026. Pascal Touchon was appointed Chairman, and Cokey Nguyen became President and CEO. ATRA stock surged by 10.0% in September 2025 and increased by 10.57% compared to the previous week in November 2025. As of November 25, 2025, the share price was $14.53, an 18.52% increase over the past year. An insider purchased 19,335 shares, while the President and CEO sold 2,915 shares.

Specific demand seasonality for Atara Biotherapeutics' products is not explicitly detailed. However, general seasonality analysis for ATRA stock indicates that historical price patterns can be analyzed by month. The nature of their products typically implies a more consistent demand driven by medical need rather than seasonal fluctuations.

Atara Biotherapeutics, Inc. is a biotechnology company focused on developing allogeneic T-cell immunotherapies for serious diseases. Their lead product candidate is Tab-cel, an allogeneic T-cell therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disease, which is in late-stage clinical trials and has received regulatory approval in some regions. Other programs included ATA188 targeting EBV in multiple sclerosis, ATA3219 (CAR T Platform) targeting CD19 for B-cell malignancies and autoimmune diseases, and ATA3431, an allogeneic, bispecific CAR directed against CD20 and CD19 for B-cell malignancies, however, development of ATA3219 and ATA3431 CAR-T programs was paused in early 2025.

Atara Biotherapeutics, Inc. is headquartered in Thousand Oaks, California, United States. The company develops therapies for patients in the United States and the United Kingdom.

Atara Biotherapeutics' reputation has been influenced by the pause of its allogeneic CAR-T cell programs and a workforce reduction of approximately 50% to preserve resources and focus on EBVALLO. The company also announced a workforce reduction of approximately 25%. The FDA's acceptance of the tab-cel BLA with Priority Review was a positive development. The company has been working to address GMP compliance issues with a third-party manufacturer to lift a clinical hold and support the EBVALLO BLA resubmission in the U.S..

Atara Biotherapeutics, Inc. stock ownership is a mix of institutional, insider, and retail investors. Approximately 21.40% to 26.12% of the company's stock is owned by institutional shareholders, insiders hold around 41.30% of the stock, and retail investors own approximately 34.76% of the stock. Major institutional owners include EcoR1 Capital, LLC, Redmile Group, LLC, Vanguard Group Inc, Marshall Wace, Llp, BlackRock, Inc., Mackenzie Financial Corp, Geode Capital Management, Llc, and Acadian Asset Management Llc. Panacea Innovation Ltd is noted as the largest individual Atara Biotherapeutics shareholder, owning 2.74 million shares, representing 37.94% of the company.